Gonadorelin
GnRH, LHRH, luteinising hormone-releasing hormone, gonadorelin acetate, gonadorelin hydrochloride, LH-RH
Gonadorelin is synthetic GnRH, chemically identical to the hormone the hypothalamus itself releases. Its four-minute half-life means everything depends on how it is delivered: a single injection is a diagnostic test, delivery by pump in physiological pulses is a genuine fertility treatment, and continuous exposure suppresses the axis entirely. Its most common use today - alongside testosterone replacement therapy - has essentially no supporting trial evidence and became popular because of a regulatory supply problem, not a scientific finding.
Mechanism
Gonadorelin is chemically identical to native gonadotrophin-releasing hormone. It binds the GnRH receptor on pituitary gonadotrophs, a Gq/11-coupled GPCR, triggering phospholipase C, IP3-mediated calcium mobilisation and protein kinase C activation, and hence exocytosis of LH and, to a lesser extent, FSH.
Everything clinically distinctive about it follows from its half-life. Because native GnRH is cleared within minutes, a single injection produces one discrete LH pulse and then nothing. That makes gonadorelin effectively three different drugs depending on delivery pattern. As a single bolus it is a diagnostic probe - the GnRH stimulation test - because the size and shape of the LH and FSH response helps distinguish pituitary from hypothalamic causes of hypogonadism and helps confirm central precocious puberty. Delivered by portable pump in physiological pulses every 60 to 120 minutes, it reconstitutes the missing hypothalamic signal in congenital hypogonadotropic hypogonadism and can induce puberty, spermatogenesis or ovulation. Delivered continuously, it does the opposite: the receptor downregulates and the axis shuts down, exactly as with a depot GnRH agonist. Dosing pattern, not dose, determines the direction of effect.
A note on taxonomy: gonadorelin is grouped here with the melanocortin and reproductive peptides for navigational convenience; it is not a melanocortin.
What the research shows
The pulsatile-therapy evidence is real but small and entirely non-randomised, and the audit of this page found it had been overstated.
In men with congenital hypogonadotropic hypogonadism, a non-randomised comparative study of 28 azoospermic men (10 on a pulsatile gonadorelin pump, 18 on cyclical hCG/hMG gonadotrophin therapy) found spermatogenesis in 90% of the pump group and 83.3% of the gonadotrophin group over 24 months, with the pump group reaching it earlier - a median of 6 months versus 14 months. A separate three-year follow-up cohort of 73 Chinese men with the condition, primarily a whole-exome sequencing study, reported spermatogenesis in roughly 70% of treated patients. A frequently cited multicentre 'efficacy and safety' study of pulsatile GnRH in this population is, on inspection, a seven-day prospective self-controlled evaluation of pump performance in 28 men that measured the LH and FSH rise over one week - it does not demonstrate induction of puberty or spermatogenesis, and the previous version of this page said it did. A 2014 review by Pitteloud and Dwyer concluded that fertility outcomes with pulsatile GnRH, hCG or combined gonadotrophin therapy are highly variable and that a large multicentre trial is still needed to establish the optimal approach. Pulsatile GnRH has similarly been used to induce ovulation in hypothalamic amenorrhoea. As a diagnostic agent, the GnRH stimulation test was validated decades ago and remains in endocrinology practice, though it has been partly displaced by GnRH-analogue stimulation tests and better basal assays.
The use driving most current interest - intermittent subcutaneous gonadorelin alongside testosterone replacement therapy, as a substitute for hCG in maintaining testicular volume and fertility - has essentially no supporting evidence. There is no published randomised trial of gonadorelin for that purpose. Nor is there good pharmacological reason to expect a peptide with a four-minute half-life, injected once or twice daily, to reproduce a pulse train the hypothalamus delivers every 90 minutes via a pump. It became popular in US telehealth practice largely because compounded hCG supply was constrained by an FDA decision, not because anyone showed it worked. That should be stated plainly: the substitution was driven by regulatory circumstance and commercial availability, not by evidence.
Evidence assessment
Limited evidence
Downgraded from 'mixed' on audit. Pulsatile pump therapy in congenital hypogonadotropic hypogonadism has a coherent physiological rationale, but every surviving citation is a small non-randomised cohort, a seven-day device study, a genetics cohort or a narrative review - there is no randomised trial. The approved human products have been withdrawn, and the dominant contemporary use alongside testosterone replacement has no trial evidence at all.
Tiers are applied consistently across the library and re-checked when new trials read out. Read the grading method.
Key studies
The Pulsatile Gonadorelin Pump Induces Earlier Spermatogenesis Than Cyclical Gonadotropin Therapy in Congenital Hypogonadotropic Hypogonadism Men Limited evidence
Spermatogenesis occurred in 90% of the pump group and 83.3% of the gonadotrophin group, with a median time to sperm appearance of 6 versus 14 months (p=0.01); skin irritation was the common adverse effect with the pump.
Efficacy and safety of pulsatile gonadotropin-releasing hormone therapy in patients with congenital hypogonadotropic hypogonadism: a multicentre clinical study Limited evidence
After one week of pulsatile GnRH, LH and FSH rose to 2.66±1.74 and 5.05±3.03 IU/L respectively, and the pump delivered reliably; two minor adverse events were judged unrelated to treatment.
Hormonal control of spermatogenesis in men: therapeutic aspects in hypogonadotropic hypogonadism Limited evidence
Fertility outcomes with pulsatile GnRH, hCG or combined gonadotrophin regimens are highly variable; the authors note a small randomised study (n=13) favouring sequential FSH pretreatment and conclude that a large multicentre trial is needed to establish the optimal approach for severe congenital hypogonadotropic hypogonadism.
Genetic Profiles and Three-year Follow-up Study of Chinese Males With Congenital Hypogonadotropic Hypogonadism Limited evidence
Sixty-two variants were identified in 51 patients (69.9%), most often in FGFR1, PROKR2 and CHD7; approximately 70% of treated patients achieved spermatogenesis over three years.
Safety
Gonadorelin is generally well tolerated. Reported effects include headache, nausea, abdominal discomfort, flushing and injection-site reactions; hypersensitivity reactions and rare anaphylaxis have been described. With pump-delivered pulsatile therapy the principal risks in women are those of ovarian stimulation - multiple pregnancy and, uncommonly, ovarian hyperstimulation syndrome, though considerably less than with injected gonadotrophins - plus catheter-site infection. Skin irritation at the pump site is a common nuisance effect. Isolated cases of pituitary apoplexy have been reported after GnRH stimulation testing in people with undiagnosed pituitary adenomas.
The limits of the safety record are what matter for how gonadorelin is actually used now. The historical safety data come from short diagnostic exposures and from supervised pump therapy in specialist centres, in cohorts numbering tens of patients. There is no controlled safety characterisation of daily or twice-daily subcutaneous injection over months or years, which is the current pattern of use. In men, non-physiological dosing schedules carry the theoretical risk of desensitising rather than stimulating the axis. Compounded product quality varies between pharmacies and is not subject to the same batch controls as an approved medicine.
Regulatory status
| Jurisdiction | Status |
|---|---|
| United Kingdom | No routinely available MHRA-licensed human gonadorelin product; the previously marketed products have been discontinued. Pulsatile GnRH therapy in the UK is provided through specialist reproductive endocrinology centres using imported or unlicensed supply under clinical governance. Gonadorelin is licensed as a veterinary medicine. Supply for human use outside a specialist or prescribing framework is unlawful. |
| United States | No FDA-approved gonadorelin product is currently marketed. Factrel (gonadorelin hydrochloride, for diagnostic use) and Lutrepulse (gonadorelin acetate, for pulsatile therapy) were both approved and have both been discontinued for commercial reasons rather than for safety or efficacy failures. Gonadorelin is now supplied almost entirely by 503A and 503B compounding pharmacies, chiefly for off-label use alongside testosterone replacement - an indication no regulator has ever evaluated. It remains separately licensed as a veterinary reproductive drug. |
| WADA (sport) | Prohibited in males at all times. WADA's Prohibited List section S2.2.1 covers luteinising hormone and chorionic gonadotrophin and their releasing factors in males, and gonadorelin is among the substances named as examples. |
Questions
No. There is no published randomised trial of gonadorelin for maintaining testicular function or fertility during testosterone replacement. It became widely used in US telehealth practice after compounded hCG supply was restricted by an FDA decision - a supply problem, not a research finding. Its four-minute half-life also makes once- or twice-daily injection a poor imitation of the 90-minute pulse pattern that actually drives the axis.
Better than for the injection-based uses, but thinner than it is usually presented. The supporting studies are small non-randomised cohorts - one comparative study had ten men in the pump arm - plus a genetics cohort and a seven-day device study. There is no randomised trial. The physiological rationale is exact and the outcome, sperm where there was none, is hard to confound, which is why the treatment is credible. But 'credible mechanism, small uncontrolled series' is not the same as proven.
Because the pituitary GnRH receptor responds to rhythm, not just exposure. Pulses roughly every 60-90 minutes sustain LH and FSH release. Continuous exposure downregulates the receptor and shuts the axis off - this is precisely how depot GnRH agonists like triptorelin achieve chemical castration. The same molecule can therefore stimulate or suppress depending entirely on how it arrives.
Not in most markets for human use. The US products, Factrel for diagnostic testing and Lutrepulse for pulsatile therapy, were both approved and have both been discontinued for commercial reasons rather than because of any safety or efficacy problem. Human supply now comes largely from compounding pharmacies. Gonadorelin does remain a licensed veterinary reproductive drug.
A diagnostic procedure in which a single bolus of gonadorelin is given and LH and FSH are measured over the following hour or two. The shape and magnitude of the response helps distinguish a pituitary cause of hypogonadism from a hypothalamic one, and helps confirm central precocious puberty in children. It is a test, not a treatment, and it has been partly superseded by GnRH-analogue stimulation tests and more sensitive basal assays.